Concepedia

Author

Alexander Harkavyi

Medway School of Pharmacy

Also Known As

A Harkavyi, A. Harkavyi, Alexander Harkavyi, Harkavyi, A

22

Publications

598

Citations

10

H-Index

29

Concepts

All Affiliations

Medway School of PharmacyUniversity of LondonUniversity College LondonKing's College SchoolUniversity of Westminster
AH

About

Alexander Harkavyi is an author at Medway School of Pharmacy specializing in medicine, neuropharmacology, and neurochemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

94

2

Neuroscience

4

4

78

3

Pharmacology

4

4

63

4

Social Sciences

3

3

63

5

Neurology

3

3

63

Alexander Harkavyi

×

9

Publications

465

Citations

9

H-Index

YearCitations

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever,

Journal of Neuroinflammation

2008

281

Dopamine-Dependent Tuning of Striatal Inhibitory Synaptogenesis

Darren Goffin, Afia B. Ali, N. Rampersaud,

Journal of Neuroscience

2010

38

RETRACTED: Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions

N. Rampersaud, Alexander Harkavyi, Giulia Maria Giordano,

Neuropeptides

2012

31

Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat

Amjad Abuirmeileh, Alexander Harkavyi, N. Rampersaud,

Journal of Pharmacy and Pharmacology

2012

30

<i>Retracted</i>: Exendin‐4 reverts behavioural and neurochemical dysfunction in a pre‐motor rodent model of Parkinson's disease with noradrenergic deficit

N. Rampersaud, Alexander Harkavyi, G Giordano,

British Journal of Pharmacology

2012

22

Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease

Amjad Abuirmeileh, Alexander Harkavyi, Rebecca Lever,

Journal of Neuroinflammation

2007

22

The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide

Amjad Abuirmeileh, Alexander Harkavyi, Ann E. Kingsbury,

Journal of the Neurological Sciences

2008

16

The CRF-like peptide urocortin greatly attenuates loss of extracellular striatal dopamine in rat models of Parkinson's disease by activating CRF1 receptors

Amjad Abuirmeileh, Alexander Harkavyi, Ann E. Kingsbury,

European Journal of Pharmacology

2008

15

Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D<sub>3</sub> Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra

Alexander Harkavyi, N. Rampersaud, Peter S. Whitton

Journal of Neurodegenerative Diseases

2013

10

Page 1